Venables, J.P. et al. Identification of alternative splicing markers for breast cancer.
Thirteen urinary nucleosides, primarily degradation products of tRNA, were evaluated as potential tumor markers for breast cancer patients.
PS species (18 1/18 1 and 18 2/18 0) levels increased in breast cancer patients and were observed to have reduced post-surgery indicating that PS can be used as early diagnostic markers for breast cancer [84].
For instance, the specific haplogroup D, and its subgroup D4a and D5 might be susceptibility genetic background markers for breast cancer and esophageal cancer in Chinese population (Fang et al., 2010).
That - at least in part - was the motivation behind the Collaborative Oncological Gene/Environment Study, or COGES, which has announced the discovery of 80 new genetic markers for breast, ovarian and prostate cancer.
We completed these studies with markers for breast stem/progenitor and differentiated luminal and myoepithelial lineage cells.
Widschwendter et al. [18] examined locus-specific methylation and found that particular DNA methylation patterns in peripheral blood may serve as surrogate markers for breast cancer.
Tissue specific and blood-based methylation markers might provide valuable information as prognostic and predictive markers for breast cancer, as well as for developing novel targeted therapeutic strategies.
Although currently used prognostic and treatment-predictive markers for breast cancer have markedly improved treatment decisions, additional markers are required to further tailor treatment for individual patients.
While additional study on the MTDH gene is necessary, variants of MTDH may prove to be potential markers for breast cancer development, prognostic indicators for disease progression, and possible foci for future targeted therapy.
If serum assays commonly measure the increase of a marker rather than its absence in cancer, our findings would help explain the current lack of suitable blood markers for breast cancer, particularly in patients with poor prognosis malignancies.
